ORM-1153
Phase 1A DAC pairing a CD123-targeting antibody with a GSPT1 degrader, in a US Phase 1 trial planned for about 42 patients with relapsed or refractory AML and other blood cancers.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has dosed the first patient in a US Phase 1 trial of its CD123-targeting DAC, ORM-1153.
Roles often seen at this stageResearch & development · Clinical & PV · Regulatory affairs
A clinical-stage biotech developing degrader-antibody conjugates (DACs) that attach protein degraders to antibodies.
A DAC pairing a CD123-targeting antibody with a GSPT1 degrader, in a US Phase 1 trial planned for about 42 patients with relapsed or refractory AML and other blood cancers.
The company's core technology combining antibodies with degraders for cell-selective protein degradation.
Dosed the first patient in the US Phase 1 trial of ORM-1153.
Received US FDA clearance of the IND for ORM-1153.
Presented preclinical ORM-1153 data at AACR 2026.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.